Upstream therapy in atrial fibrillation: Traveling up the river to find the source

Heart Rhythm

Volumn 7, Issue 4, 2010, Pages 529-530

  Anné, Wim ^a   Duytschaever, Mattias ^a  

^a General Hospital St Jan   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ION CHANNEL; POLYUNSATURATED FATTY ACID;

BABESIOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOG; DRUG ACTIVITY; EDITORIAL; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HEART MUSCLE FIBROSIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; RANDOMIZED CONTROLLED TRIAL;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FUNCTION; DISEASE MODELS, ANIMAL; FATTY ACIDS, UNSATURATED; HEART ATRIA; HUMANS;

EID: 77949466974     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2010.02.021     Document Type: Editorial

References (10)

1. Ausma J., van der Velden H.M., Lenders M.H., et al. Reverse structural and gap-junctional remodeling after prolonged atrial fibrillation in the goat. Circulation 107 (2003) 2051-2058
2. Li D., Shinagawa K., Pang L., et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104 (2001) 2608-2614
3. Ramadeen A., Laurent G., dos Santos C., et al. n-3 Polyunsaturated fatty acids alter expression of fibrotic and hypertrophic genes in a dog model of atrial cardiomyopathy. Heart Rhythm 7 (2010) 520-528
4. Everett T.H., Li H., Mangrum J.M., et al. Electrical, morphological, and ultrastructural remodeling and reverse remodeling in a canine model of chronic atrial fibrillation. Circulation 102 (2000) 1454-1460
5. Anne W., Willems R., Holemans P., et al. Self-terminating AF depends on electrical remodeling while persistent AF depends on additional structural changes in a rapid atrially paced sheep model. J Mol Cell Cardiol 43 (2007) 148-158
6. Savelieva I., Kourliouros A., and Camm J. Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance. Naunyn Schmiedebergs Arch Pharmacol (2009) [Epub ahead of print]
7. Healey J.S., Baranchuk A., Crystal E., Morillo C.A., Garfinkle M., Yusuf S., et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 45 (2005) 1832-1839
8. Disertori M., Latini R., Barlera S., et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 360 (2009) 1606-1617
9. Sanders P., Morton J.B., Kistler P.M., Vohra J.K., Kalman J.M., and Sparks P.B. Reversal of atrial mechanical dysfunction after cardioversion of atrial fibrillation: implications for the mechanisms of tachycardia-mediated atrial cardiomyopathy. Circulation 108 (2003) 1976-1984
10. Kuppahally SS, Akoum N, Burgon NS, et al. Left atrial strain and strain rate in patients with paroxysmal and persistent atrial fibrillation: relationship to left atrial structural remodeling detected by delayed enhancement-MRI. Circ Cardiovasc Imaging [Epub ahead of print].